LivaNova Announces Publication of 36-Month CORE-VNS Study Results

LivaNova has published the results of the 36-month CORE-VNS study in the journal Neuromodulation, demonstrating a 76% median reduction in seizure frequency for patients with drug-resistant epilepsy using VNS Therapy devices. The study also indicated a 73% decrease in seizure-related hospitalizations and a drop in emergency department visits from 32% at baseline to 15% at 36 months. Management emphasized these findings as proof of the therapy's long-term effectiveness in managing epilepsy.